EANS-Interim Report: OMV Aktiengesellschaft / Zwischenmitteilung
Further inquiry note: Branche: Oil & Gas - Downstream activities ISIN: AT0000743059 WKN: 874341 Index: ATX Prime, ATX Börsen: Wien / official dealing ...
mehr
Ergebnis der Suchanfrage nach @r@@r@Politik
Inhalte
- Kategorie:
- Sprache:
-
Medien:
Alle
- Zeitraum:
- Zeitraum:Gesamt
680 Treffer
EANS-Adhoc: ElringKlinger buoyed by upturn in sales and cost reductions in Q3 2009
Further inquiry note: For further information, please contact: ElringKlinger AG Investor Relations / Corporate Communications Stephan Haas Max-Eyth-Straße 2 72581 Dettingen Phone: +49 0 7123-724-137 E-mail: stephan.haas@elringklinger.de Branche: Automotive Equipment ISIN: DE0007856023 WKN: 785602 Index: MDAX, Classic All Share, Prime All Share Börsen: Frankfurt / ...
mehrBoehringer Ingelheim Receives Approval From the European Commission for Mirapexin(R)/Sifrol(R) Prolonged-Release, Once Daily Tablet for the Treatment of Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - New Formulation Brings the Established Efficacy of Mirapexin(R)/Sifrol(R) to Patients With Parkinson's Disease in the Convenience of a Once Daily Dose Boehringer Ingelheim today announced that the Mirapexin(R)/Sifrol(R) (pramipexole) new prolonged-release , once daily tablet ...
mehrEANS-News: IAA 2009: ElringKlinger focuses on engine downsizing and CO2 reduction
Further inquiry note: For further information, please contact: ElringKlinger AG Corporate Communications Max-Eyth-Straße 2, 72581 Dettingen / Erms Phone: +49 (0)7123-724-640 / 137 Fax: +49 (0)7123-724-641 E-mail: stephan.haas@elringklinger.de karl-heinz.app@elringklinger.de Branche: Automotive Equipment ISIN: DE0007856023 WKN: 785602 Index: MDAX, Classic All Share, ...
mehrEANS-Interim Report: OMV Aktiengesellschaft / Interim Announcement
Further inquiry note: Branche: Oil & Gas - Downstream activities ISIN: AT0000743059 WKN: 874341 Index: ATX Prime, ATX Börsen: Wien / official dealing ...
mehrHead-to-Head Trial Demonstrates Viramune(R)'s Similar Efficacy and Superior Effect on Lipid Profile Compared to atazanavir/ritonavir
Cape Town, South Africa (ots/PRNewswire) - - For Medical Media Outside the US Only Results from the ARTEN* trial presented at the 5th International AIDS Society (IAS) conference in Cape Town, South Africa demonstrated non-inferiority regarding efficacy between Viramune(R) (nevirapine) and ritonavir boosted ...
mehr
EANS-News: WACKER optimizes its global production network
- CONCENTRATION OF INDIVIDUAL WAFER DIAMETERS AT LEAD SITES AND STRUCTURAL IMPROVEMENTS AT WACKER SILICONES - IMPAIRMENTS OF SOME 120 MILLION AT SILTRONIC, EXPECTED REDUCTION OF NEARLY 800 JOBS AT SILTRONIC AND WACKER SILICONES BY END OF 2010 - CONTROL AND PROFIT TRANSFER AGREEMENT BETWEEN SILTRONIC AND WACKER REDUCES TAX RATE - PERSONNEL DIRECTOR SITTENTHALER: I SEE A GOOD CHANCE OF IMPLEMENTING THE PLANNED JOB CUTS ...
mehrEANS-Adhoc: WACKER Optimizes its Global Production Network
Further inquiry note: Joerg Hoffmann Investor Relations Tel.: +49 (0)89 6279 1633 E-Mail: joerg.hoffmann@wacker.com Branche: Chemicals ISIN: DE000WCH8881 WKN: WCH888 Index: Midcap Market Index, MDAX, CDAX, Classic All Share, HDAX, Prime All Share Börsen: Frankfurt / regulated dealing/prime standard ...
mehrEuropean Commission Approves Statement on Lipid Improvement for VIRAMUNE(R) Label
Ingelheim, Germany (ots/PRNewswire) - - For Medical Media Outside the US only Boehringer Ingelheim announced today that the European Commission has approved an update of the Summary of Product Characteristics (SmPC) for VIRAMUNE(R) (nevirapine) in the treatment of patients with HIV. The decision followed a positive recommendation by the Committee for Medical Products ...
mehrBoehringer Ingelheim Receives Positive Recommendation From European Scientific Committee for a New Once Daily Mirapexin(R) (Pramipexole) Formulation for the Treatment Of Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - For non-U.S. Healthcare Media Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending the approval of a once daily formulation for Mirapexin(R) / ...
mehrNew Data From Boehringer Ingelheim's Ongoing Linagliptin Trial Programme Show Promising Safety and Efficacy Results
Ingelheim, Germany (ots/PRNewswire) - - Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting Study results presented for the first time in the scientific sessions of this year's American Diabetes Association Annual ...
mehrOutcome of New Mirapexin(R)/Sifrol(R) (Pramipexole) Study set to Change Treatment of Depressive Symptoms in Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - New Study Shows That Mirapexin(R)/Sifrol(R) (Pramipexole) Relieves Depressive Symptoms of Parkinson's Disease (PD), a Common Non-Motor Symptom Affecting PD Patients' Quality of Life - For Non-US Healthcare Media To view the Multimedia News Release, go to: ...
mehr
New Study Results Support Once Daily, Prolonged Release Formulation of Mirapexin(R)/Sifrol(R) (Pramipexole) for the Treatment of Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - Data for the Once Daily Mirapexin(R)/Sifrol(R) (Pramipexole) Formulation Under Development Show Efficacy, Safety and Tolerability Outcomes Comparable to the Current Immediate Release Formulation for the Treatment of Parkinson's Disease For non-US Healthcare Media First data ...
mehrNo Increased Risk of Treatment-Induced Augmentation in Restless Legs Syndrome (RLS) Demonstrated in Long-Term Placebo-Controlled Study With Mirapexin(R) / Sifrol(R) (Pramipexole)
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media outside the U.S.A. New data presented today at the 61st Annual Meeting of the American Academy of Neurology (AAN), in Seattle, U.S.A. show that augmentation did not significantly differ in RLS patients treated with Mirapexin(R) /Sifrol(R) (pramipexole*) ...
mehrAtrium European Real Estate Limited
EANS-Adhoc: Atrium European Real Estate Limited / ATRIUM COMPLETES FIRST ROMANIAN SHOPPING CENTRE
Further inquiry note: Financial Dynamics: +44 (0)20 7831 3113 Richard Sunderland Laurence Jones Richard.sunderland@fd.com Branche: Real Estate ISIN: AT0000660659 WKN: 066065 Index: Standard Market Continous Börsen: Wiener Börse AG / official market ...
mehrECASS 3 Study Receives Recognition From the European Stroke Organisation and The Lancet
Ingelheim, Germany (ots/PRNewswire) - - ESO Recommends Extended Time Window for Actilyse(R) INGELHEIM, Germany, January 30 /PRNewswire/ -- - For Healthcare Media outside the U.S.A., Canada, and Japan Based on key results from the European Cooperative Acute Stroke Study (ECASS 3), the European Stroke Organisation (ESO) now recommends that Actilyse(R) (alteplase) be ...
mehrFirst Pivotal Trials Begin for Boehringer Ingelheim's Novel Triple Angiokinase Inhibitor Vargatef(TM) (BIBF 1120)
Ingelheim, Germany, November 17 (ots/PRNewswire) - - Progress Continues Across Expanding Oncology Pipeline With Two Compounds now in Phase III Clinical Development and a Potential First-in-Class Polo-Like Kinase 1 Inhibitor Soon to Enter Phase II - For non-US Healthcare Media Boehringer Ingelheim has marked a new ...
mehreuro adhoc: OMV Aktiengesellschaft / Interim Announcement
Further inquiry note: Branche: Oil & Gas - Downstream activities ISIN: AT0000743059 WKN: 874341 Index: ATX Prime, ATX Börsen: Wiener Börse AG / official dealing ...
mehr
Telmisartan (MICARDIS(R)) as Effective as Ramipril But With Better Long-Term Tolerability in High-Risk Cardiovascular Asian Patients
Beijing (ots/PRNewswire) - New results from the landmark ONTARGET(R) Trial show that, in Asian patients at high risk of cardiovascular disease (CVD), telmisartan (MICARDIS(R)) 80mg is as effective as, and significantly better tolerated than, ramipril 10mg in reducing the risk of cardiovascular death, heart attack, ...
mehrFrom Curiosity to Discovery: Boehringer Ingelheim's Pipeline Update Unveils Novel Investigational Compounds Heralding the Company's Entry Into Type 2 Diabetes
Ingelheim and Biberach, Germany (ots/PRNewswire) - - Boehringer Ingelheim Oncology Pipeline Advances: Two Leading Compounds are Entering Phase III Trials - Boehringer Ingelheim's Investigational Compound in Development for the Treatment of Pre-Menopausal Women Suffering From Hypoactive Sexual Desire Disorder (HSDD) ...
mehrRecent Research Shows Significant Benefits in Acute Ischaemic Stroke With Actilyse(R) Beyond Currently Approved Three Hour Treatment Window
Ingelheim, Germany (ots/PRNewswire) - - For Healthcare Media Outside the U.S.A., Canada, and Japan - Favourable Safety and Efficacy Profile of Actilyse(R) Confirmed by ECASS 3 Study Investigating Treatment in an Extended Time Window up to 4.5 Hours After Symptom Onset First results from ECASS 3 (European Cooperative ...
mehrChange-over of CEAG AG Board of Directors
Felix Zimmermann to become sole CEO of power supply and charger manufacturer -Lonng-term Chairman and CEO Rolf Endress and CFO Frank Gumbinger leave the company by mutual consent Change due to new size and focus of CEAG Further inquiry note: Gudrun Richter Investor Relations Telefon: +49 (0) 2532-81-158 E-Mail: richter@friwo.de Branche: Semiconductors & active components ISIN: DE0006201106 WKN: 620110 Index: CDAX ...
mehrFirst Landmark ARB Trial Against Placebo Shows MICARDIS(R) (Telmisartan) Reduces the Risk of Cardiovascular Death, Heart Attack and Stroke in ACE-Intolerant High-Risk Patients(1)
Munich, Germany (ots/PRNewswire) - - TRANSCEND(R), Parallel Trial to ONTARGET(R), Confirms Long-Term Protective Benefits and Excellent Tolerability Profile of Telmisartan 80mg(1) on Top of Current Best Standard of Care MUNICH, Germany, August 31 /PRNewswire/ -- - For non-US Healthcare Media The results of the ...
mehreuro adhoc: Mergers - Acquisitions - Takeovers / PALFINGER AG - Company Takeover/aerial working platforms
Further inquiry note: Hannes Roither, PALFINGER AG Company Spokesperson Phone +43 662 46 84-2260 mailto: h.roither@palfinger.com www.palfinger.com Branche: Machine Manufacturing ISIN: AT0000758305 WKN: 919964 Index: ATX Prime, ATX Börsen: Wiener Börse AG / official market ...
mehr
MICARDIS(R)- Based Regimens Help More Patients Achieve Their Blood Pressure Goals
Berlin (ots/PRNewswire) - - For non-US Healthcare Media and non-UK Healthcare Media - New Studies Show Benefits of MICARDIS(R) (Telmisartan) in Combination With Amlodipine and Hydrochlorothiazide The results of two new studies of MICARDIS(R) (telmisartan) in free combination with amlodipine or fixed combination with hydrochlorothiazide (HCTZ) 25 mg confirm that a ...
mehrNew Data Shows Pramipexole (Mirapexin(R)/Sifrol(R)) Can Significantly Reduce Limb Pain in Patients With Restless Legs Syndrome (RLS)
Ingelheim, Germany (ots/PRNewswire) - - First Ever Study to Demonstrate Efficacy of Pramipexole in Treating RLS-Associated Limb Pain - For Healthcare Media Outside the U.S.A. A new study demonstrating that pramipexole (Mirapexin(R)/Sifrol(R)) can significantly reduce RLS-associated limb pain in patients with ...
mehrLeading Analyst Firm rates USU Valuemation in the area of IT Asset Management as "promising"
Further inquiry note: USU AG Internationalization & Partner, Marc Kothé, Phone.: +49.69.430 53 644 , Mobile: +49.173.310 3435 , Fax: +49.69.430 53 645, m.kothe@usu.de Corporate Communications, Dr. Thomas Gerick, Phone.: +49.7141.4867-440 , Mobile: +49.178.555.6664 , Fax: +49.7141.4867-909, t.gerick@usu.de http://www.usu-ag.com (english) , http://www.usu.de ...
mehreuro adhoc: OMV Aktiengesellschaft / Interim Announcement
Further inquiry note: Branche: Oil & Gas - Downstream activities ISIN: AT0000743059 WKN: 874341 Index: ATX Prime, ATX Börsen: Wiener Börse AG / official dealing ...
mehrElringKlinger lifts stake in Marusan Corporation to 50%
Further inquiry note: Stephan Haas Investor Relations Manager Telefon: +49(0)7123 724-137 E-Mail: stephan.haas@elringklinger.de Branche: Automotive Equipment ISIN: DE0007856023 WKN: 785602 Index: SDAX, CDAX, Classic All Share, Prime All Share Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Berlin / free trade Börse Düsseldorf / free trade Börse München / free trade Börse Stuttgart / regulated ...
mehreuro adhoc: Software AG / Management Changes / Software AG: Changes to the Executive Board
Further inquiry note: Otmar F. Winzig Vice President Investor Relations & Compliance Phone: +49 6151 92 1669 Email: otmar.winzig@softwareag.com Norbert Eder Vice President Corporate Communications Phone: +49 6151 92 1146 Email: norbert.eder@softwareag.com Branche: Software ISIN: DE0003304002 WKN: 330400 Index: TecDAX, CDAX, HDAX, Prime All Share, Technologie All ...
mehr
Vorherige14151617181920212223Nächste